DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at several upcoming investor conferences. These conferences include:

• Steven Pacelli, EVP, Strategy and Corporate Development, will present an update on DexCom at the Lazard Capital Markets 9th Annual Healthcare Conference in New York City on Tuesday, November 13, 2012 at 9:00 a.m. (EST). The presentation, which will occur live at The Pierre, will be concurrently webcast.
• Mr. Pacelli will also present an update on DexCom at the Stephens Inc. Fall Investment Conference in New York City on Wednesday, November 14, 2012 at 10:00 a.m. (EST). The presentation, which will occur live at The New York Palace, will be concurrently webcast.
• Kevin Sayer, President, will present an update on DexCom at the Credit Suisse Healthcare Conference in Phoenix, Arizona on Thursday, November 15, 2012, at 3:00 p.m. (MST). The presentation, which will occur live at the Arizona Biltmore Resort and Spa, will be concurrently webcast.
• Terry Gregg, Chief Executive Officer, will present an update on DexCom at the 24th Annual Piper Jaffray Health Care Conference in New York City on Tuesday, November 27, 2012 at 10:30 a.m. (EST). The presentation, which will occur live at The New York Palace, will be concurrently webcast.
• Mr. Gregg will also present an update on DexCom at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York City on Tuesday, December 4, 2012, at 9:00 a.m. (EST). The presentation, which will occur live at Le Parker Meridien, will be concurrently webcast.

The link to each webcast will be available on the DexCom website at www.dexcom.com under the investor relations, events and webcast section, and will be archived for future reference.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.

Cautionary Statement Regarding Forward Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ending September 30, 2012, as filed with the Securities and Exchange Commission on November 1, 2012.